Relazione del Prof. Carlo Gambacorti-Passerini per la Festa di Aip Lmc del 05/10/2019 a Villa Reale - Monza

1. Carlo Gambacorti
1999-2009:
Cos’era la cura per la LMC prima del 1999
Significato per i pazienti

2. It was 1996….

3. 2019

5. Nuovo ambulatorio LMC

9. Cytogenetic Abnormality of CML:
The Philadelphia Chromosome

10. Effect of STI571 on Growth of
Bcr-Abl–Positive and –Negative Cell Lines
Adapted from Gambacorti-Passerini C et al. Blood Cells Mol Dis. 1997;23:380.
*Bcr-Abl-negative cell lines
†Bcr-Abl-positive cell lines
U937*
KG1*
KCL22*
K562†
KU812†
SU DHL1†
STI571 Concentration (mM)
% Control CPM
0 0.1 0.3 1 3 10
0
20
40
60
80
100
120

13. Chronic Phase patients
30.00
20.00
23.08
45.16
32.0028.57
44.83
30.00
96.77
76.92
80.00
70.00
73,68
54.84 55.17
71.43 68.00
3.23
0.00
20.00
40.00
60.00
80.00
100.00
0 3 6 9 12 15 18 21 24
Therapy, month
%patients
% pt without response % pt with major or complete response

15. PATIENTS ENROLLED
3-10
28-46
128-151
384

18. 0
50000
100000
150000
200000
250000
300000
350000
400000
2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050
Prevalence
Year
Incidence 2000: 1/100.000
Incidence 2000: 1,5/100.000
Incidence 2000: 2/100.000
Projection of CML Prevalence Up to 2050
Assumptions: Population: 500 Mill., mortality: 2% per year,
Incidence increasing by about 0.01/100.000 per year
20%-25% increase per year
in projected prevalence

22. • Insoddisfazione per la situazione presente

23. • Vedere la luce in fondo al tunnel

24. • Non fare troppi calcoli “politici” o di
convenienza

25. • Lasciare il posto in cui velocemente
transitiamo migliore di come l’abbiamo
trovato.